A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases

Suhag H Parikh, Adam Mendizabal, Cara L Benjamin, Krishna V Komanduri, Jeyaraj Antony, Aleksandra Petrovic, Gregory Hale, Timothy A Driscoll, Paul L Martin, Kristin M Page, Ketti Flickinger, Jerelyn Moffet, Donna Niedzwiecki, Joanne Kurtzberg, Paul Szabolcs, Suhag H Parikh, Adam Mendizabal, Cara L Benjamin, Krishna V Komanduri, Jeyaraj Antony, Aleksandra Petrovic, Gregory Hale, Timothy A Driscoll, Paul L Martin, Kristin M Page, Ketti Flickinger, Jerelyn Moffet, Donna Niedzwiecki, Joanne Kurtzberg, Paul Szabolcs

Abstract

Reduced-intensity conditioning (RIC) regimens have the potential to decrease transplantation-related morbidity and mortality. However, engraftment failure has been prohibitively high after RIC unrelated umbilical cord blood transplantation (UCBT) in chemotherapy-naïve children with nonmalignant diseases (NMD). Twenty-two children with a median age of 2.8 years, many with severe comorbidities and prior viral infections, were enrolled in a novel RIC protocol consisting of hydroxyurea, alemtuzumab, fludarabine, melphalan, and thiotepa followed by single UCBT. Patients underwent transplantation for inherited metabolic disorders (n = 8), primary immunodeficiencies (n = 9), hemoglobinopathies (n = 4) and Diamond Blackfan anemia (n = 1). Most umbilical cord blood (UCB) units were HLA-mismatched with median infused total nucleated cell dose of 7.9 × 10(7)/kg. No serious organ toxicities were attributable to the regimen. The cumulative incidence of neutrophil engraftment was 86.4% (95% confidence interval [CI], 65% to 100%) in a median of 20 days, with the majority sustaining > 95% donor chimerism at 1 year. Cumulative incidence of acute graft-versus-host disease (GVHD) grades II to IV and III to IV by day 180 was 27.3% (95% CI, 8.7% to 45.9%) and 13.6% (95 CI, 0% to 27.6%), respectively. Cumulative incidence of extensive chronic GVHD was 9.1% (95% CI, 0% to 20.8%). The primary causes of death were viral infections (n = 3), acute GVHD (n = 1) and transfusion reaction (n = 1). One-year overall and event-free survivals were 77.3% (95% CI, 53.7% to 89.8%) and 68.2% (95% CI, 44.6% to 83.4%) with 31 months median follow-up. This is the first RIC protocol demonstrating durable UCB engraftment in children with NMD. Future risk-based modifications of this regimen could decrease the incidence of viral infections. (www.clinicaltrials.gov/NCT00744692).

Keywords: Hemophagocytic lymphohistiocytosis (HLH); Nonmalignant diseases; Pediatric disorders; Reduced-intensity conditioning; Thalassemia; Umbilical cord blood transplantation.